Opens in a new tab or window Adding pembrolizumab to docetaxel failed to improve survival in metastatic castration-resistant prostate cancer. Overall survival was 19-20 months regardless of ...

Furthermore, docetaxel (the drug of choice for the ... BM: Brain metastasis; CRPC: Castration-resistant prostate cancer; CT: Computed tomography; NA: Not assessed; NMR: Nuclear magnetic resonance ...

Men with advanced prostate cancer are being denied access to a breakthrough treatment for the disease – despite it being low cost, and based on UK research. The chemotherapy drug docetaxel has ...

The mainstay of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) remains a combination of androgen deprivation therapy along with standard-of-care androgen receptors ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Adding pembrolizumab to docetaxel does not appreciably affect efficacy outcomes among patients who received prior treatment for metastatic castration-resistant prostate cancer (mCRPC).

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...